



Bloomberg	ALKEM IN
Equity Shares (m)	120
M.Cap.(INRb)/(USDb)	653.3 / 7.2
52-Week Range (INR)	5934 / 4492
1, 6, 12 Rel. Per (%)	-7/-2/3
12M Avg Val (INR M)	849

#### Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	145.2	160.8	177.2
EBITDA	29.8	32.1	36.1
Adjusted PAT	24.8	21.6	23.8
EBIT Margin (%)	18.0	17.6	18.1
Adj EPS (INR)	207.7	180.8	199.2
EPS Gr. (%)	14.7	-12.9	10.2
BV/Sh. (INR)	1,148.2	1,263.8	1,397.8
<b>Ratios</b>			
Net D-E	-0.1	0.0	-0.1
RoE (%)	19.3	15.0	15.0
RoCE (%)	18.7	14.7	14.7
Payout (%)	28.9	36.0	32.7
<b>Valuations</b>			
P/E (x)	26.3	30.2	27.4
EV/EBITDA (x)	21.3	20.3	17.8
Div. Yield (%)	0.9	1.0	1.0
FCF Yield (%)	2.9	-1.5	2.3
EV/Sales (x)	4.4	4.0	3.6

#### Shareholding Pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	51.2	51.2	55.7
DII	21.5	21.9	18.0
FII	10.0	9.5	10.2
Others	17.3	17.4	16.2

FII includes depository receipts

## Alkem Lab

**CMP:INR5,464**      **TP: INR5,525 (+1%)**      **Neutral**

### Expanding scope of business in the Medtech segment

#### Widening reach; product approval to drive profitable growth

- Alkem Lab (ALKEM) is advancing its MedTech strategy through the acquisition of up to a 55% stake in Occlutech for ~EUR99m (~INR10.6b), gaining control of a specialist in minimally invasive devices for congenital heart disease, stroke prevention, and heart failure.
- Occlutech is a leading structural heart and closure device company with over 10 product lines, presence in more than 70 countries, manufacturing in Germany and Turkey, and over 200,000 devices sold; it ranks as the third-largest player in the global occluder segment.
- The company has delivered ~17% revenue CAGR over CY22–24 (EUR43m in CY24; ~EUR49m est. CY25), with CY25 revenue/EBITDA/loss at ~EUR49m/EUR2m/EUR6.8m; margins remain in single digits (~5%), with the company targeting expansion to ~23–24% over the next 3–4 years.
- The transaction aligns with ALKEM's broader MedTech focus on musculoskeletal and cardiovascular segments within a large global opportunity (USD680b MedTech; USD87b Cardiovascular), where it has already established a base in orthopedics through a hybrid entry model and the Bombay Ortho acquisition.
- For ALKEM, acquiring an R&D-focused company with a presence in developed markets is strategic move to scale its MedTech business. Occlutech's profitability has yet to improve despite over 15 years of presence in this space, primarily due to an enhanced focus on R&D. ALKEM intends to drive profitability by expanding its reach and accelerating product approvals/launches. The valuation appears decent, provided performance progresses in line with guidance.
- ALKEM is diversifying its growth levers into the MedTech and CDMO space, in addition to its domestic formulations segment. On an overall basis, we expect 10.5%/12% CAGR in revenue/EBITDA over FY26-28. Earnings are expected to remain stable over FY26-28 due to a step-up in tax rate. The valuation adequately factors in the upside. Reiterate Neutral on the stock.

### Occlutech acquisition strategically compelling; profitability execution key monitorable

- Occlutech is a leading specialist provider of minimally invasive structural heart occlusion devices, with presence across the congenital heart disease, stroke prevention, and heart failure segments. The company has commercialized its products in over 70 countries, with manufacturing facilities in Germany and Turkey.
- Its portfolio comprises over 10 product lines across three therapeutic areas, with over 200,000 devices sold since inception.
- It has delivered ~17% sales CAGR over CY22-24 to EUR43m and is estimated to reach EUR49m (~INR4.9b) in CY25, implying ~16.5% CAGR over CY22-25. Over the next five years, ALKEM intends to scale revenue to INR10b+ and expand EBITDA margin from ~5% currently to ~20-25%.

**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Research Analyst: Vipul Mehta** (Vipul.Mehta@MotilalOswal.com) | **Eshita Jain** (Eshita.Jain@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**


Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- This implies EV/EBITDA of ~15x/~7x on CY28E/CY30E EBITDA. The acquisition is 3.6x CY25 sales.
- ALKEM plans to leverage Occlutech as a global MedTech entry platform across Japan, the US, and Europe.


### Highlights from the management commentary

- ALKEM has guided for overall MedTech revenue to reach INR15b, with an EBITDA margin of 22-25% over the next five years.
- Occlutech has been focusing on R&D, with INR1.2b spent in CY24. The R&D spend may rise to INR1.5b, including the development of the LAA product.
- Investment related to Patent Foramen Ovale (PFO) is largely complete, and the company expects US approval by Jun'27.
- Launching existing products in different markets (LATAM, APAC), securing PFO approval for the US market (Jun'27; the US has better pricing than EU), and cost optimization are expected to drive overall profitability for Occlutech.
- Occlutech has a field strength of 65 to cater to the western EU market.
- ALKEM expects 45-46% of sales from EU and 20% from US in the occlutech business over the next five years, from the current 71%/14% from EU/US.
- As part of MedTech, ALKEM will focus on load-bearing large joints in the orthopaedic and cardiovascular segments.
- For products like occluders, management highlighted that the interoperative procedure is as critical as the product itself in influencing a surgeon's choice for treating patients
- Within the musculoskeletal space, ALKEM has set a target of 250k implants over the next five years and a 10% market share in India.
- As part of its global expansion, CE approval for the knee/hip products is expected in 4QFY28.
- ALKEM indicated that the knee/hip products will be launched in 2Q/4QFY27, respectively, in the Indian market.

**Exhibit 1: P/E chart**



**Exhibit 2: EV/EBITDA chart**




### ALKEM to acquire majority stake in Occlutech

- Occlutech is a leading specialist provider of minimally invasive cardiac devices.
- The company has developed, produced, and commercialized first-class, minimally invasive, cardiac implants for congenital heart disease, stroke prevention, and heart failure.
- Its devices are sold to hospitals and clinics in over 70 countries. It has manufacturing facilities in Germany and Turkey.
- Occlutech has more than 10 product lines across three therapeutic areas and has sold over 200,000 devices since its inception.

### Occlutech: Mid-teen revenue growth with single-digit EBITDA margins

- Occlutech delivered a 17% sales CAGR over CY22-24, reaching EUR43m. With estimated sales of EUR49m (INR4.9b) in CY25, the sales CAGR over CY22-25 is expected at 16.5%. The company reported a net loss of EUR20m in CY24.

### Exhibit 3: ALKEM guides for INR6b in revenue in CY26; up 23% YoY



- The loss is expected to reduce to EUR6.8m in CY25. ALKEM has guided for 23% YoY growth in CY26, targeting revenue of INR6b from this entity.
- With a growth potential of 14-15% CAGR over the next five years, ALKEM intends to scale this business to INR10b+.
- From the current 5% EBITDA margin, ALKEM intends to scale EBITDA margin to 20-25% over the next five years.
- ***Assuming the above performance, revenue/EBITDA are projected at INR8b/INR1.2b in CY28, and INR10.5b/INR2.6b in CY30. EV/EBITDA is estimated at 18x/8x for CY28/CY30.***

### ALKEM has identified musculoskeletal and cardiovascular as key focus areas

- In line with its diversification strategy into high-growth adjacencies, ALKEM has forayed into the MedTech space in FY25, with musculoskeletal (Orthopedic) and cardiovascular designated as primary focus segments, alongside a selective presence in IVD and wound care.
- The addressable opportunity spans the USD680b global MedTech market, including USD49b in orthopedics and USD87b in cardiovascular, in addition to the USD16b Indian market, which remains structurally under-penetrated.
- The strategy is supported by structural tailwinds in emerging markets, including rising disease awareness and screening, expanding reimbursement frameworks,

increasing insurance penetration, and improving clinician capabilities, driving the adoption of advanced interventional therapies.

- Healthcare infrastructure expansion and decentralization of tertiary care into Tier-2 and Tier-3 cities are expected to improve access and sustain procedural volume growth.
- ALKEM approved an aggregate investment of INR2.5b in ALKEM MedTech in FY25, including INR1.5b for the acquisition of Bombay Ortho and ~INR1b toward working capital requirements.

#### **Foundation established in musculoskeletal through a hybrid entry model**

- ALKEM MedTech has implemented a hybrid entry model in musculoskeletal, combining a technology transfer and licensing agreement with a US-based orthopaedic company (for knee and hip implant portfolio rights in India) and the acquisition of Bombay Ortho's manufacturing assets, accelerating the time-to-market.
- The manufacturing facility, equipped with cleanrooms, precision CNC machines, and robotic grinding and polishing systems, provides immediate production capability with modular scalability to meet projected demand over the next 2–3 years, with plans to triple capacity over the near term.
- Through Bombay Ortho, ALKEM has reported >50% sequential implant growth QoQ (Dec'25YTD) and built a base of 150+ repeat customers, reflecting stable demand and surgeon engagement.
- The portfolio comprises NEXSTEP Total Hip Replacement System (uncemented stem and acetabular cup) and ACTIKNEE Total Knee Replacement System, addressing primary hip and knee arthroplasty, with further launches planned in 2QFY27 (Knee) and 4QFY27 (Hip) under the technology transfer arrangement.
- Over the medium term, the company targets 250k+ implants and ~10% share of the Indian large joints market within five years, supported by expansion to 4,000+ implanters and phased international rollout through CE (4QFY28) and CIS (1QFY28) approvals.

#### **Entering the global cardiovascular device market via Occlutech acquisition**

- ALKEM MedTech is entering the cardiovascular segment through the acquisition of Occlutech, providing immediate exposure to structural heart and closure devices, along with an established global product portfolio and commercial footprint to support faster scale-up.
- The company has outlined a three-pillar cardiovascular strategy comprising: 1) the acquisition of an established global cardio asset to secure immediate scale and market access, 2) portfolio expansion via the established structural heart platform to strengthen product breadth and revenue diversification, and 3) cost optimization initiatives to enhance gross margins and operating leverage.
- The global cardiovascular market is estimated at USD87.6b, representing a structurally growing opportunity; Cardiac Devices account for ~68% of the market, while Vascular/Peripheral contributes ~28%.
- The Cardiac Devices segment (USD59.1b) is diversified across Cardiac Rhythm Management/Monitoring (55%), Coronary/Interventional Cardiology (25%), Structural Heart Devices (15%), and Heart Failure Devices (5%).

- The Structural Heart Device (SHD) market is estimated at USD8.8b, of which USD2.2b relates to closure devices, including Occluders (USD0.7b) and Left Atrial Appendage devices (USD1.4b).

#### Exhibit 4: Overview of the cardiac device market

Heart Condition	Description	Treatment Options	Device Types	Market Share (USD\$b)
Structural Heart Defects	<ul style="list-style-type: none"> <li>❖ Holes or unusual connections in the heart that people are born with; affect blood flow inside the heart</li> </ul>	<ul style="list-style-type: none"> <li>❖ Medications (rare), open-heart surgery, transcatheter device closure</li> </ul>	ASD, PFO, PDA, VSD	8.8
Valve Disease	<ul style="list-style-type: none"> <li>❖ Valves don't open or close properly, making it harder for blood to move in the right direction; causes fatigue, shortness of breath, or heart failure</li> </ul>	<ul style="list-style-type: none"> <li>❖ Valve repair/replacement surgery, TAVR, TMVR</li> </ul>	TAVI valves, TMVR clips	-
Heart Failure	<ul style="list-style-type: none"> <li>❖ Heart becomes too weak or too stiff to pump blood well; leads to tiredness, swelling, and fluid buildup</li> </ul>	<ul style="list-style-type: none"> <li>❖ Medication, ICD/CRT implants, ventricular assist devices (VADs), AF</li> </ul>	ICDs, CRTs, AF shunts, VADs	3.0
Coronary Artery Disease	<ul style="list-style-type: none"> <li>❖ Arteries that feed the heart get narrowed or blocked (usually by cholesterol), leading to chest pain or heart attacks</li> </ul>	<ul style="list-style-type: none"> <li>❖ Medication, angioplasty + stents, bypass surgery</li> </ul>	Bypass stents, drug-eluting stents (DES)	14.8
Arrhythmias	<ul style="list-style-type: none"> <li>❖ Heart beats too fast, too slow, or irregularly; may feel like fluttering or skipping and increase stroke risk</li> </ul>	<ul style="list-style-type: none"> <li>❖ Pacemakers, ICDs, ablation</li> </ul>	Pacemakers, ICDs	32.5
Stroke Risk from Atrial Fibrillation	<ul style="list-style-type: none"> <li>❖ Blood can pool in the heart during AF, forming clots that may travel to the brain and cause a stroke</li> </ul>	<ul style="list-style-type: none"> <li>❖ Blood thinners, LAA closure</li> </ul>	LAA devices	-

Source: Company, MOFSL

#### Occlutech positioned to benefit from the oligopolistic SHD market

- The SHD treatment is witnessing a structural shift from open-heart surgery toward minimally invasive transcatheter interventions, driven by: a) an aging population, b) rising atrial fibrillation incidence, c) increasing diagnosis of congenital heart defects, and d) growing adoption of cath-lab-based procedures.
- The occluder segment remains an oligopolistic market, with key global players such as Abbott and Lifetech Scientific, alongside select Indian participants, including SMT and Merill Lifescience, reflecting high entry barriers and limited competition.
- In this concentrated competitive landscape, Occlutech stands to benefit from rational pricing dynamics, strong regulatory moats, and sustained demand growth within closure therapies.

#### Occlutech ranks as the third-largest player in the space

- Notably, Occlutech is the third-largest company in the occluder segment. About 85% of revenue comes from Western Europe and US markets.
- The PFO is yet to receive USFDA approval. That said, Occlutech's PFO demonstrates a 99% procedural success rate and a 95% effective closure rate after six months, with most of R&D spend for this product largely completed.
- The USFDA approved Occlutech's Atrial Septal Defect (ASD) Occluder and the associated Pistol Pusher delivery system in Dec'23 for treating patients with

ostium secundum-type ASD. This minimally invasive, nitinol-based device enables permanent, non-surgical closure of holes in the heart.


- Occlutech has partnered with B. Braun Interventional Systems to commercialize its device in the US following approval. The FDA granted breakthrough designation to the Atrial Flow Regulator (AFR) for pulmonary arterial hypertension (PAH). At the time of Occlutech's approval, the US ASD closure market was USD40m. The company has gained a 5% market share within 1.5 years.

#### **Plan of action by ALKEM**

- In addition to the amount paid for acquisition, ALKEM would be investing INR1b-INR2b to fund the R&D program.
- Occlutech would be utilized as a platform for MedTech offerings in markets like Japan, the US, and Europe in the cardiovascular segment.
- Considering this business has a strong gross margin of 73%, ALKEM plans to build operating leverage by enhancing offerings and expanding reach.


## Story in charts

**Exhibit 5: Expect 9.5% sales CAGR over FY25-28 in the US**




Source: Company, MOFSL

**Exhibit 6: EBITDA margin to expand ~100bp over FY25-28**




Source: Company, MOFSL

**Exhibit 7: Expect revenue CAGR of 11% over FY25-28**




Source: Company, MOFSL

**Exhibit 8: Expect India sales CAGR of 10% over FY25-28**




Source: Company, MOFSL

**Exhibit 9: Return ratios expected to moderate going ahead**



Source: Company, MOFSL

**Exhibit 10: Expect earnings to post a 3% CAGR over FY25-28**



Source: Company, MOFSL

## Financials and Valuations

Consolidated - Income Statement							INRm
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Total Income from Operations</b>	<b>1,06,342</b>	<b>1,15,993</b>	<b>1,26,676</b>	<b>1,29,645</b>	<b>1,45,206</b>	<b>1,60,834</b>	<b>1,77,229</b>
Change (%)	20.2	9.1	9.2	2.3	12.0	10.8	10.2
<b>Total Expenditure</b>	<b>85,813</b>	<b>99,198</b>	<b>1,04,221</b>	<b>1,04,524</b>	<b>1,15,381</b>	<b>1,28,774</b>	<b>1,41,164</b>
<b>EBITDA</b>	<b>20,529</b>	<b>16,795</b>	<b>22,455</b>	<b>25,121</b>	<b>29,825</b>	<b>32,061</b>	<b>36,065</b>
Margin (%)	19.3	14.5	17.7	19.4	20.5	19.9	20.3
Depreciation	3,040	3,104	2,993	3,572	3,687	3,809	4,064
<b>EBIT</b>	<b>17,490</b>	<b>13,690</b>	<b>19,462</b>	<b>21,550</b>	<b>26,138</b>	<b>28,252</b>	<b>32,001</b>
Int. and Finance Charges	524	1,074	1,124	1,217	1,389	1,064	998
Other Income	1,627	2,161	3,108	4,937	4,883	5,837	4,556
<b>PBT bef. EO Exp.</b>	<b>18,592</b>	<b>14,778</b>	<b>21,446</b>	<b>25,270</b>	<b>29,632</b>	<b>33,024</b>	<b>35,560</b>
EO Items	-150	-1,730	-1,215	0	-399	0	0
<b>PBT after EO Exp.</b>	<b>18,443</b>	<b>13,048</b>	<b>20,231</b>	<b>25,270</b>	<b>29,233</b>	<b>33,024</b>	<b>35,560</b>
Current Tax	1,640	2,980	2,117	3,110	4,179	10,568	10,846
Deferred Tax	0	0	0	0	0	0	0
Tax Rate (%)	8.9	22.8	10.5	12.3	14.3	32.0	30.5
Less: Minority Interest	300	226	157	505	556	840	900
<b>Reported PAT</b>	<b>16,503</b>	<b>9,842</b>	<b>17,958</b>	<b>21,655</b>	<b>24,498</b>	<b>21,616</b>	<b>23,814</b>
<b>Adjusted PAT</b>	<b>16,516</b>	<b>12,678</b>	<b>19,091</b>	<b>21,655</b>	<b>24,828</b>	<b>21,616</b>	<b>23,814</b>
Change (%)	2.6	-23.2	50.6	13.4	14.7	-12.9	10.2
Margin (%)	15.5	10.9	15.1	16.7	17.1	13.4	13.4

## Consolidated - Balance Sheet

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	239	239	239	239	239	239	239
Total Reserves	86,140	90,214	1,02,882	1,19,610	1,37,024	1,50,847	1,66,869
<b>Net Worth</b>	<b>86,379</b>	<b>90,453</b>	<b>1,03,121</b>	<b>1,19,849</b>	<b>1,37,263</b>	<b>1,51,086</b>	<b>1,67,108</b>
Minority Interest	2,094	3,897	4,023	4,488	4,488	4,488	4,488
Deferred Tax Liabilities	0	0	0	0	0	0	0
Total Loans	26,466	13,775	14,032	13,302	13,302	13,302	13,302
<b>Capital Employed</b>	<b>1,14,939</b>	<b>1,08,125</b>	<b>1,21,176</b>	<b>1,37,638</b>	<b>1,55,052</b>	<b>1,68,876</b>	<b>1,84,898</b>
Gross Block	35,948	36,835	43,260	46,607	52,742	66,771	78,378
Less: Accum. Deprn.	13,077	16,181	19,174	22,745	26,433	30,242	34,306
<b>Net Fixed Assets</b>	<b>22,871</b>	<b>20,654</b>	<b>24,086</b>	<b>23,862</b>	<b>26,310</b>	<b>36,529</b>	<b>44,073</b>
Goodwill on Consolidation	6,146	4,796	4,642	4,662	4,662	4,662	4,662
Capital WIP	3,395	3,103	1,586	5,481	2,847	12,320	4,215
<b>Total Investments</b>	<b>3,710</b>	<b>6,218</b>	<b>4,838</b>	<b>18,455</b>	<b>18,455</b>	<b>18,455</b>	<b>18,455</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>91,477</b>	<b>89,770</b>	<b>1,05,449</b>	<b>1,07,070</b>	<b>1,33,762</b>	<b>1,32,833</b>	<b>1,53,912</b>
Inventory	30,055	26,075	26,612	29,224	32,876	37,044	40,609
Account Receivables	18,846	21,322	22,528	24,663	28,643	32,608	35,931
Cash and Bank Balance	25,786	25,786	15,694	15,631	30,184	16,595	26,036
Loans and Advances	16,790	16,587	40,616	37,552	42,059	46,586	51,335
<b>Curr. Liability &amp; Prov.</b>	<b>25,753</b>	<b>29,442</b>	<b>34,572</b>	<b>39,273</b>	<b>48,365</b>	<b>53,306</b>	<b>57,800</b>
Account Payables	11,734	11,650	17,481	18,394	20,547	22,579	24,752
Other Current Liabilities	7,955	10,370	12,824	15,906	17,815	19,732	21,744
Provisions	6,064	7,421	4,267	4,973	10,003	10,994	11,305
<b>Net Current Assets</b>	<b>65,725</b>	<b>60,329</b>	<b>70,877</b>	<b>67,797</b>	<b>85,397</b>	<b>79,528</b>	<b>96,111</b>
Deferred Tax assets	13,093	13,025	15,148	17,383	17,383	17,383	17,383
<b>Appl. of Funds</b>	<b>1,14,939</b>	<b>1,08,125</b>	<b>1,21,177</b>	<b>1,37,638</b>	<b>1,55,053</b>	<b>1,68,877</b>	<b>1,84,897</b>

## Financials and Valuations

### Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>							
EPS	<b>138.1</b>	<b>106.0</b>	<b>159.7</b>	<b>181.1</b>	<b>207.7</b>	<b>180.8</b>	<b>199.2</b>
Cash EPS	163.6	132.0	184.7	211.0	238.5	212.7	233.2
BV/Share	723	757	863	1,002	1,148	1,264	1,398
DPS	59.0	50.0	40.0	45.0	50.0	55.0	55.0
Payout (%)	50.7	72.0	31.6	29.4	28.9	36.0	32.7
<b>Valuation (x)</b>							
P/E	39.6	51.5	34.2	30.2	26.3	30.2	27.4
Cash P/E	33.4	41.4	29.6	25.9	22.9	25.7	23.4
P/BV	7.6	7.2	6.3	5.5	4.8	4.3	3.9
EV/Sales	6.2	5.5	5.1	5.0	4.4	4.0	3.6
EV/EBITDA	31.9	38.2	29.0	25.9	21.3	20.3	17.8
Dividend Yield (%)	1.1	0.9	0.7	0.8	0.9	1.0	1.0
FCF per share	65.5	121.5	147.3	148.6	156.4	-81.4	121.9
<b>Return Ratios (%)</b>							
RoE	20.6	14.3	19.7	19.4	19.3	15.0	15.0
RoCE	17.1	11.3	18.3	18.6	18.7	14.7	14.7
RoIC	21.6	13.6	20.3	19.2	22.2	17.1	17.3
<b>Working Capital Ratios</b>							
Fixed Asset Turnover (x)	3.0	3.1	2.9	2.8	2.8	2.4	2.3
Asset Turnover (x)	0.9	1.1	1.0	0.9	0.9	1.0	1.0
Inventory (Days)	103	82	77	82	83	84	84
Debtor (Days)	65	67	65	69	72	74	74
Creditor (Days)	40	37	50	52	52	51	51
Working Cap. Turnover (Days)	137	109	159	147	139	143	144
<b>Leverage Ratio (x)</b>							
Current Ratio	3.6	3.0	3.1	2.7	2.8	2.5	2.7
Interest Cover Ratio	33.4	12.8	17.3	17.7	18.8	26.5	32.1
Debt/Equity	0.0	-0.1	0.0	0.0	-0.1	0.0	-0.1

### Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	INRm FY28E
OP/(Loss) before Tax	18,443	13,048	20,231	25,270	29,632	33,024	35,560
Depreciation	3,040	3,104	2,993	3,572	3,687	3,809	4,064
Interest & Finance Charges	-703	1,074	1,124	-3,720	-3,494	-4,772	-3,559
Direct Taxes Paid	-3,969	-2,734	-4,069	-3,110	-4,179	-10,568	-10,846
(Inc)/Dec in WC	-5,450	3,268	-516	3,017	-3,446	-7,719	-7,142
<b>CF from Operations</b>	<b>11,361</b>	<b>17,759</b>	<b>19,763</b>	<b>25,028</b>	<b>22,201</b>	<b>13,774</b>	<b>18,077</b>
<b>CF from Operating incl EO</b>	<b>11,110</b>	<b>16,825</b>	<b>19,482</b>	<b>25,028</b>	<b>22,201</b>	<b>13,774</b>	<b>18,077</b>
(Inc)/Dec in FA	-3,280	-2,297	-1,868	-7,262	-3,502	-23,502	-3,502
<b>Free Cash Flow</b>	<b>7,830</b>	<b>14,528</b>	<b>17,614</b>	<b>17,767</b>	<b>18,699</b>	<b>-9,728</b>	<b>14,575</b>
(Pur)/Sale of Investments	-12,051	1,955	-10,612	-13,617	0	0	0
Others	980	1,471	2,395	4,937	4,883	5,837	4,556
<b>CF from Investments</b>	<b>-14,351</b>	<b>1,128</b>	<b>-10,085</b>	<b>-15,942</b>	<b>1,381</b>	<b>-17,665</b>	<b>1,054</b>
Inc/(Dec) in Debt	8,628	-11,408	-5,132	-730	0	0	0
Interest Paid	-401	-905	-913	-1,217	-1,389	-1,064	-998
Dividend Paid	-4,219	-5,295	-5,405	-6,376	-7,084	-7,793	-7,793
<b>CF from Fin. Activity</b>	<b>3,796</b>	<b>-16,388</b>	<b>-19,489</b>	<b>-9,149</b>	<b>-9,029</b>	<b>-9,697</b>	<b>-9,690</b>
<b>Inc/Dec of Cash</b>	<b>555</b>	<b>1,565</b>	<b>-10,093</b>	<b>-62</b>	<b>14,552</b>	<b>-13,589</b>	<b>9,441</b>
Opening Balance	1,705	2,297	3,862	-6,231	-6,293	8,260	-5,329
<b>Closing Cash and Cash Eq.</b>	<b>2,297</b>	<b>3,862</b>	<b>-6,231</b>	<b>-6,293</b>	<b>8,260</b>	<b>-5,329</b>	<b>4,112</b>
Bank Balances	23,489	21,924	21,924	21,924	21,924	21,924	21,924
<b>Total Cash and Cash Eq.</b>	<b>25,786</b>	<b>25,786</b>	<b>15,694</b>	<b>15,631</b>	<b>30,184</b>	<b>16,595</b>	<b>26,036</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRIL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.